Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Recordati Industria Chimica e Farmaceutica SPA ( (IT:REC) ) has issued an announcement.
Recordati’s shareholders approved the 2025 financial statements and a higher total dividend of €1.34 per share, up 5.5% year on year, confirming the group’s commitment to rewarding investors as first-quarter 2026 revenues rose to €713.4 million despite adverse currency effects. The meeting also renewed authorization for treasury share buybacks, approved a new 2026–2028 performance share plan and the 2026 remuneration policy, appointed a new Board of Statutory Auditors for 2026–2028 and granted the board a five-year mandate for share capital increases and potential convertible bond issues up to 10% of share capital, strengthening its financial and governance flexibility.
The most recent analyst rating on (IT:REC) stock is a Buy with a EUR57.50 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
More about Recordati Industria Chimica e Farmaceutica SPA
Recordati Industria Chimica e Farmaceutica S.p.A. is an Italian pharmaceutical group focused on prescription medicines, rare disease therapies and specialty products for international markets. The company operates globally with a strategy that combines organic growth, targeted acquisitions and shareholder returns, supported by active capital management and equity-based incentive plans.
Average Trading Volume: 384,959
Technical Sentiment Signal: Strong Buy
Current Market Cap: €10.27B
For a thorough assessment of REC stock, go to TipRanks’ Stock Analysis page.